Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T22:29:01.992Z.
Calculation as of: 2026-10-06T22:29:01.992Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.06B
Free Cash Flow Yield
N/A
TTM Avg
11.85%
3Y Avg
12.74%
5Y Avg
12.74%
Market Cap
$2.05B
Free Cash Flow Yield
2.42%
TTM Avg
2.35%
3Y Avg
0.78%
5Y Avg
0.92%
Market Cap
$2.03B
Free Cash Flow Yield
10.74%
TTM Avg
9.62%
3Y Avg
8.45%
5Y Avg
5.63%
Market Cap
$2.02B
Free Cash Flow Yield
17.67%
TTM Avg
9.91%
3Y Avg
8.62%
5Y Avg
8.62%
Market Cap
$2.11B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
Free Cash Flow Yield
N/A
TTM Avg
1.82%
3Y Avg
1.82%
5Y Avg
1.82%
Market Cap
$2.02B
Free Cash Flow Yield
8.60%
TTM Avg
6.70%
3Y Avg
5.44%
5Y Avg
5.44%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 11.85% | 12.74% | 12.74% |
| Alvotech (ALVO)vs › | $2.08B | N/A | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 2.42% | 2.35% | 0.78% | 0.92% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 10.74% | 9.62% | 8.45% | 5.63% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 17.67% | 9.91% | 8.62% | 8.62% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 1.82% | 1.82% | 1.82% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 8.60% | 6.70% | 5.44% | 5.44% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
